5-cyano-2'-deoxyuridine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 493224 |
| CHEMBL ID | 373885 |
| SCHEMBL ID | 336438 |
| MeSH ID | M0416326 |
| Synonym |
|---|
| 1-(4-hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidine-5-carbonitrile |
| 5-cn-2'-durd |
| 5-cyano-durd |
| 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-2,4-dioxo-pyrimidine-5-carbonitrile |
| 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,4-dioxopyrimidine-5-carbonitrile |
| CHEMBL373885 , |
| bdbm50000967 |
| 26639-00-9 |
| SCHEMBL336438 |
| DTXSID90333233 |
| 5-cyano-2'-deoxyuridine |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Thymidine phosphorylase | Homo sapiens (human) | Km | 49.0000 | 0.1600 | 0.1600 | 0.1600 | AID211066 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| mitochondrial genome maintenance | Thymidine phosphorylase | Homo sapiens (human) |
| angiogenesis | Thymidine phosphorylase | Homo sapiens (human) |
| pyrimidine nucleobase metabolic process | Thymidine phosphorylase | Homo sapiens (human) |
| pyrimidine nucleoside metabolic process | Thymidine phosphorylase | Homo sapiens (human) |
| chemotaxis | Thymidine phosphorylase | Homo sapiens (human) |
| signal transduction | Thymidine phosphorylase | Homo sapiens (human) |
| cell differentiation | Thymidine phosphorylase | Homo sapiens (human) |
| regulation of myelination | Thymidine phosphorylase | Homo sapiens (human) |
| dTMP catabolic process | Thymidine phosphorylase | Homo sapiens (human) |
| regulation of transmission of nerve impulse | Thymidine phosphorylase | Homo sapiens (human) |
| regulation of gastric motility | Thymidine phosphorylase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| 1,4-alpha-oligoglucan phosphorylase activity | Thymidine phosphorylase | Homo sapiens (human) |
| protein binding | Thymidine phosphorylase | Homo sapiens (human) |
| growth factor activity | Thymidine phosphorylase | Homo sapiens (human) |
| thymidine phosphorylase activity | Thymidine phosphorylase | Homo sapiens (human) |
| protein homodimerization activity | Thymidine phosphorylase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| cytosol | Thymidine phosphorylase | Homo sapiens (human) |
| cytosol | Thymidine phosphorylase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID280941 | Cytotoxicity against mouse L1210/0 cells after 48 hrs | 2007 | Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7 | Probing the anticancer activity of nucleoside analogues: a QSAR model approach using an internally consistent training set. |
| AID1136933 | Inhibition of Escherichia coli B thymidine kinase using [2-14C]-thymidine as substrate assessed as formation of [14C]-TMP at 2 mM after 10 mins by liquid scintillation spectrometric analysis relative to control | 1979 | Journal of medicinal chemistry, Dec, Volume: 22, Issue:12 | Design of species- or isozyme-specific enzyme inhibitors. 2. Differences between a bacterial and a mammalian thymidine kinase in the effect of thymidine substituents on affinity for the thymidine site. |
| AID1135480 | Antiviral activity against Vaccinia virus infected in primary rabbit kidney cells assessed as inhibition of virus-induced cytopathogenicity | 1977 | Journal of medicinal chemistry, Jul, Volume: 20, Issue:7 | Improved synthesis and in vitro antiviral activities of 5-cyanouridine and 5-cyano-2'-deoxyuridine. |
| AID1124544 | Competitive inhibition of thymidine kinase in BHK21 (C13) cells using thymidine as substrate assessed as formation of TMP by Lineweaver-Burk plot analysis | 1979 | Journal of medicinal chemistry, Jun, Volume: 22, Issue:6 | Design of species- or isozyme-specific enzyme inhibitors. 1. Effect of thymidine substituents on affinity for the thymidine site of hamster cytoplasmic thymidine kinase. |
| AID1135478 | Antiviral activity against Vaccinia virus infected in human skin fibroblasts assessed as inhibition of virus-induced cytopathogenicity | 1977 | Journal of medicinal chemistry, Jul, Volume: 20, Issue:7 | Improved synthesis and in vitro antiviral activities of 5-cyanouridine and 5-cyano-2'-deoxyuridine. |
| AID232840 | Ratio of Vmax to that of dThd (Vmax = 0.14) | 1980 | Journal of medicinal chemistry, Aug, Volume: 23, Issue:8 | Thymidine phosphorylase. Substrate specificity for 5-substituted 2'-deoxyuridines. |
| AID1135479 | Antiviral activity against Herpes simplex virus 1 infected in human skin fibroblasts assessed as inhibition of virus-induced cytopathogenicity | 1977 | Journal of medicinal chemistry, Jul, Volume: 20, Issue:7 | Improved synthesis and in vitro antiviral activities of 5-cyanouridine and 5-cyano-2'-deoxyuridine. |
| AID1135481 | Antiviral activity against Herpes simplex virus 1 infected in primary rabbit kidney cells assessed as inhibition of virus-induced cytopathogenicity | 1977 | Journal of medicinal chemistry, Jul, Volume: 20, Issue:7 | Improved synthesis and in vitro antiviral activities of 5-cyanouridine and 5-cyano-2'-deoxyuridine. |
| AID270072 | Antileishmanial activity against Leishmania donovani LV9 promastigotes by MTT method | 2006 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 16, Issue:19 | Structurally diverse 5-substituted pyrimidine nucleosides as inhibitors of Leishmania donovani promastigotes in vitro. |
| AID156400 | Concentration required to inhibit incorporation of [1,'2'-3H]dUrd into DNA of primary rabbit kidney (PRK) cells by 50% | 1981 | Journal of medicinal chemistry, Apr, Volume: 24, Issue:4 | Synthesis and antiviral activity of 5-[(cyanomethylene)oxy]-2'-deoxyuridine. |
| AID211066 | Michaelis-Menten constant (Km) against horse liver thymidine phosphorylase | 1980 | Journal of medicinal chemistry, Aug, Volume: 23, Issue:8 | Thymidine phosphorylase. Substrate specificity for 5-substituted 2'-deoxyuridines. |
| AID156514 | Concentration required to inhibit incorporation of [Me-3H]-dThd into DNA of primary rabbit kidney (PRK) cells by 50% | 1981 | Journal of medicinal chemistry, Apr, Volume: 24, Issue:4 | Synthesis and antiviral activity of 5-[(cyanomethylene)oxy]-2'-deoxyuridine. |
| AID1136932 | Inhibition of Escherichia coli B thymidine kinase using [2-14C]-thymidine as substrate assessed as formation of [14C]-TMP at 0.5 mM after 10 mins by liquid scintillation spectrometric analysis relative to control | 1979 | Journal of medicinal chemistry, Dec, Volume: 22, Issue:12 | Design of species- or isozyme-specific enzyme inhibitors. 2. Differences between a bacterial and a mammalian thymidine kinase in the effect of thymidine substituents on affinity for the thymidine site. |
| AID1135483 | Dissociation constant, pKa of the compound by spectrophotometric analysis | 1977 | Journal of medicinal chemistry, Jul, Volume: 20, Issue:7 | Improved synthesis and in vitro antiviral activities of 5-cyanouridine and 5-cyano-2'-deoxyuridine. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||